{"id":"topical-metronidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Dryness or peeling"},{"rate":null,"effect":"Metallic taste (if absorbed systemically)"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":{"chemblId":"CHEMBL137","moleculeType":"Small molecule","molecularWeight":"171.16"},"_dailymed":{"setId":"05707735-e676-412a-9a77-ebd003afb16c","title":"METRONIDAZOLE (METRONIDAZOLE TOPICAL) GEL [ENCUBE ETHICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metronidazole is a nitroimidazole antimicrobial that penetrates bacterial and protozoal cells, causing DNA strand breakage and cell death. When applied topically, it also exerts anti-inflammatory effects by suppressing neutrophil migration and reducing production of inflammatory mediators, making it particularly effective for conditions like rosacea and bacterial vaginosis where both microbial and inflammatory components are present.","oneSentence":"Topical metronidazole reduces inflammation and bacterial overgrowth in skin conditions by disrupting microbial DNA and reducing pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:29:25.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rosacea"},{"name":"Bacterial vaginosis (topical formulation)"},{"name":"Anaerobic bacterial skin infections"},{"name":"Inflammatory acne"}]},"trialDetails":[{"nctId":"NCT05929794","phase":"PHASE4","title":"Pharmacokinetics of Transdermal Metronidazole","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Iowa","startDate":"2024-02-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT07406152","phase":"NA","title":"Efficacy and Safety of ZKARE® Gel and Its Accessory ZKAPI® in the Treatment of Chronic Ulcers.","status":"RECRUITING","sponsor":"i+Med S.Coop.","startDate":"2025-11-14","conditions":"Chronic Ulcers","enrollment":134},{"nctId":"NCT07392047","phase":"PHASE4","title":"Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2026-02","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT06836401","phase":"PHASE4","title":"Topical Metronidazole vs Control in Reducing Periodontal Pockets in a Split Mouth Clinical Trial","status":"COMPLETED","sponsor":"University of Salamanca","startDate":"2018-10-10","conditions":"Periodontal Disease, Periodontal Inflammation","enrollment":20},{"nctId":"NCT06582043","phase":"NA","title":"Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea","status":"COMPLETED","sponsor":"NAOS Argentina S.A.","startDate":"2024-05-16","conditions":"Rosacea, Redness, Telangiectasia","enrollment":70},{"nctId":"NCT04998513","phase":"NA","title":"Medical Versus Surgical Treatment for Peritonsillar Abscesses","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2022-01","conditions":"Peritonsillar Abscess, Surgical Incision","enrollment":""},{"nctId":"NCT02682485","phase":"PHASE2","title":"Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2017-03-03","conditions":"Anastomotic Leak, Rectal Cancer","enrollment":""},{"nctId":"NCT05677945","phase":"NA","title":"3Mixtatin Versus Modified 3Mix-MP in Lesion Sterilization and Tissue Repair for Treatment of Necrotic Primary Molars","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-03","conditions":"Necrotic Primary Molars","enrollment":24},{"nctId":"NCT01426269","phase":"PHASE4","title":"Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-09","conditions":"Rosacea","enrollment":235},{"nctId":"NCT00668655","phase":"","title":"An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-02","conditions":"Rosacea","enrollment":30},{"nctId":"NCT04276298","phase":"PHASE2, PHASE3","title":"Topical Analgesia Post-Haemorrhoidectomy","status":"COMPLETED","sponsor":"University of Auckland, New Zealand","startDate":"2020-09-01","conditions":"Hemorrhoid Pain, Hemorrhoids","enrollment":192},{"nctId":"NCT05038605","phase":"NA","title":"Topical vs Oral Metronidazole After Benign Anorectal Surgery","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2020-01-24","conditions":"Hemorrhoids, Anal Fissure, Anal Fistula","enrollment":108},{"nctId":"NCT03343509","phase":"PHASE4","title":"Topical Versus Oral Metronidazole Following Excisional Haemorrhoidectomy","status":"COMPLETED","sponsor":"University of Auckland, New Zealand","startDate":"2019-03-11","conditions":"Hemorrhoids, Postoperative Pain","enrollment":120},{"nctId":"NCT02393937","phase":"PHASE3","title":"A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea","status":"COMPLETED","sponsor":"bioRASI, LLC","startDate":"2015-02","conditions":"Papulopustular Rosacea, Erythematotelangiectatic Rosacea","enrollment":963},{"nctId":"NCT02602470","phase":"","title":"Preferences & Treatment Satisfaction Drivers in Rosacea Patients","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01-08","conditions":"Rosacea","enrollment":206},{"nctId":"NCT00855595","phase":"PHASE4","title":"Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-02","conditions":"Papulopustular Rosacea","enrollment":207},{"nctId":"NCT03656484","phase":"PHASE2","title":"New Periodontitis Treatment Based on Hyaluronic Acid and Melatonin","status":"COMPLETED","sponsor":"Concordia Dent Srl","startDate":"2019-01-15","conditions":"Chronic Periodontitis","enrollment":50},{"nctId":"NCT01951768","phase":"PHASE4","title":"Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2013-09","conditions":"Diabetic Foot Ulcer","enrollment":88},{"nctId":"NCT04125706","phase":"NA","title":"Locally Delivered Antibiotics for the Treatment of Periodontitis","status":"UNKNOWN","sponsor":"Riyadh Elm University","startDate":"2019-11-01","conditions":"Periodontitis","enrollment":44},{"nctId":"NCT02197182","phase":"EARLY_PHASE1","title":"LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study","status":"TERMINATED","sponsor":"CDA Research Group, Inc.","startDate":"2014-06","conditions":"Bacterial Vaginosis (BV)","enrollment":50},{"nctId":"NCT03412071","phase":"NA","title":"Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2017-12-07","conditions":"Foreskin HIV Susceptibility","enrollment":125},{"nctId":"NCT01848379","phase":"NA","title":"White Blood Cell Signaling and Defense Mechanisms in Patients With Diabetes Mellitus Type 2 and Periodontitis","status":"UNKNOWN","sponsor":"Zentrum fuer Zahn-, Mund- und Kieferheilkunde","startDate":"2012-01","conditions":"Chronic Periodontitis, Diabetes Mellitus, Type 2","enrollment":45},{"nctId":"NCT00642473","phase":"PHASE2","title":"A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":34},{"nctId":"NCT02394821","phase":"PHASE3","title":"Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2013-09","conditions":"Neoplasm, Wounds and Injuries","enrollment":24},{"nctId":"NCT01230814","phase":"PHASE2","title":"Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-04","conditions":"Bacterial Vaginosis, Candidiasis, Trichomoniasis","enrollment":234},{"nctId":"NCT02142543","phase":"EARLY_PHASE1","title":"The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2012-03","conditions":"Minor Recurrent Aphthous Stomatitis Lesions","enrollment":23},{"nctId":"NCT02052999","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients","status":"COMPLETED","sponsor":"Amorepacific Corporation","startDate":"2013-02","conditions":"Erythematotelangiectatic Rosacea, Papulopustular Rosacea","enrollment":80},{"nctId":"NCT01513863","phase":"PHASE1","title":"A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2011-08","conditions":"Rosacea","enrollment":602},{"nctId":"NCT00774722","phase":"PHASE2, PHASE3","title":"A Randomised Controlled Trial of the Use of Topical Metronidazole (10%) to Reduce Pain After Haemorrhoidectomy","status":"COMPLETED","sponsor":"S.L.A. Pharma AG","startDate":"2006-09","conditions":"Haemorrhoidectomy","enrollment":59},{"nctId":"NCT00509639","phase":"PHASE3","title":"Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease","status":"COMPLETED","sponsor":"S.L.A. Pharma AG","startDate":"2005-05","conditions":"Crohn's Disease","enrollment":74},{"nctId":"NCT00495313","phase":"PHASE4","title":"Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens","status":"COMPLETED","sponsor":"CollaGenex Pharmaceuticals","startDate":"2007-03","conditions":"Rosacea","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":229,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rozex 0.75%"],"phase":"marketed","status":"active","brandName":"Topical metronidazole","genericName":"Topical metronidazole","companyName":"University of Toronto","companyId":"university-of-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical metronidazole reduces inflammation and bacterial overgrowth in skin conditions by disrupting microbial DNA and reducing pro-inflammatory cytokine production. Used for Rosacea, Bacterial vaginosis (topical formulation), Anaerobic bacterial skin infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}